Norway’s Nykode Eyes NASDAQ As Pipeline Advances
Executive Summary
CEO Michael Engsig tells Scrip that his well-capitalized company has ambitious plans for US expansion and is looking to set up an autoimmune diseases arm to add to its oncology efforts.
You may also be interested in...
Europe’s Biotech Sector Still In Reasonable Shape
Money may have become too tight to mention for many biotechs and the IPO window in Europe is not just shut but boarded up. However, big pharma’s need to replenish the pipeline has become urgent and the major players are looking to tap into the continent’s early-stage companies which are driving innovation and provide them with much-needed cash.
Still Looking For A Cancer Vaccine Breakthrough, Roche Signs $200m Vaccibody Deal
Despite a recent disappointment in a similar partnership with BioNTech, Genentech is pushing ahead with its neoantigen-targeting strategy.
Nordics BioPharma Sector In Rude Health Despite Global Downturn
When it comes to building innovative pipelines and raising cash, Scandinavia is giving the rest of Europe a run for its money.